The Globe and Mail reports in its Wednesday, Nov. 4, edition that BMO Capital Markets analyst Alexander Pearce has reiterated his "outperform" recommendation and $150 share target for Cameco. The Globe's David Leeder writes that analysts on average target the shares at $176.69. Mr. Pearce says in a note: "Cameco's Q3 disappointed on a combination of lower sales, and higher costs/purchases. Nonetheless, incorporating sales/production guidance 'tightening' and higher costs drives relatively minor changes to our full-year forecast, with 2026/2027 EBITDA now $1.8-billion/$2.4-billion (down 5 per cent/down 4 per cent).
The updates do imply a significantly stronger Q4 (EBITDA $624-million, vs $267-million in Q3), which combined with a robust outlook for uranium should see some positive momentum return to the stock into the new year. However, we have trimmed the target price to reflect lower current sentiment in the sector." The Globe reported on Sept. 25 that TD Cowen analyst Craig Hutchison had reaffirmed his "buy" recommendation for Cameco. It was then worth $124.69. The Globe reported on Oct. 6 that National Bank Financial analyst Mohamed Sidibe rated Cameco "outperform." The shares could then be had for $132.27.
© 2026 Canjex Publishing Ltd. All rights reserved.